“Protocol 2603: Multi-center, open-label randomized study of single or double myeloablative cord blood transplantation with or without infusion of off-the-shelf ex vivo expanded cryospreserved cord blood progenitor cells in patients with hematologic malignancies”
ID Number 16-0906Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
You may qualify to take part in this research study because you are eligible for an umbilical cord blood transplant.
Transplantation with cord blood is a standard therapy in many transplant hospitals around the world. One disadvantage of cord blood transplantation is that it takes longer for blood counts to recover in patients treated with cord blood compared to patients who receive other types of transplant.
Recruiting Patients: Yes